A: Data are the change in A1C (%) from baseline over the course of the study in the per-protocol population with type 1 diabetes managed with CSII with insulin lispro (insulin pump therapy) or insulin glargine plus insulin lispro MDI therapy. ♦, CSII; ■, MDI. B: Data are the mean eight-point blood glucose profiles at baseline and end point over the course of the study for people in the per-protocol population randomized to insulin glargine plus insulin lispro MDI therapy. ♦, baseline; ■, end point. C: Data are the mean eight-point blood glucose profiles at baseline and end point over the course of the study for people in the per-protocol population randomized to CSII with insulin lispro (insulin pump therapy). ♦, baseline; ■, end point. D: Data are the number of hypoglycemic events by visit for the two insulin regimens (safety population). ♦, CSII; ■, MDI.